ITGAV and prostate carcinoma: Integrin receptor antagonists, in the form of RGD-antagonists or antibodies, have been shown to decrease angiogenesis, tumor growth and metastasis in several solid tumor types in which ITGAV is upregulated, including breast cancer, melanoma and prostate cancer.